Q8 and Q8 annex An industry Perspective
|
|
- Bethany Harvey
- 5 years ago
- Views:
Transcription
1 Workshop on Implementation of ICH Q8/Q9/Q10 and Other Quality Guidelines Beijing December 2008 Q8 and Q8 annex An industry Perspective Brian Withers, Abbott Laboratories, United Kingdom I attend this conference as an individual expert and not as an EFPIA representative. The views expressed here are my personal views and may not be understood or quoted as being made on behalf of EFPIA or in any way reflecting the position of EFPIA
2 Content Q8 and Q8R QbD Design Space Control Strategy Benefits Of QbD Flexible Regulatory approaches Implementing QbD
3 July 2003: An ICH vision Our vision: The future Pharmaceutical Quality System Quality Risk Management The Regulatory Quality System Quality Risk Management (Q9) For companies with : 1. Good design and control strategies 2. Good Risk Management strategies 3. Good Quality Systems Quality Systems Quality by Design (Pharmaceutical Development) Existing GMP s Quality by Design (Q8) Quality Systems (Q10) Reduced regulatory burden: Reduction of submissions on changes/variations Inspection of quality systems We are responsible for ensuring the quality of product we manufacture
4 The Opportunity Pharmaceutical Quality Risk Development: + Management + Quality by Q9 Design Q8 Modern Effective Pharmaceutical Quality Systems Q10 Lower Risk Operations Innovation and Continual Improvement Optimized Change Management Process Flexible Regulatory Approaches
5 Structure of Q8 Q8 is a 2 part guideline Part 1 Core document Baseline expectations Optional information Regulatory Flexibility Part 2 Exemplifies Quality by Design References to use of risk management Focus on guiding towards Desired State Step 4: Nov 2005 Step 4 Nov 2008
6 Q8 What is it? The Pharmaceutical Development section provides an opportunity to present the knowledge gained through the application of scientific approaches and quality risk management to the development of a product and its manufacturing process.
7 Q8 an opportunity for change Traditional Empirical Data Driven Retrospective Test to document quality Acceptance criteria based on limited batch data Variability not understood and avoided Q8 Systematic Future Knowledge driven Prospective Science and Risk based Acceptance criteria based on patient needs Variability explored and understood (Design Space) Adapted from J Berridge
8 Q8: Pharmaceutical Development Parent guideline Introduced the general principles of pharmaceutical development Components of the drug product Formulation development Manufacturing development Introduced new concepts Minimal versus enhanced Design space Real time release (testing)
9 Q8 Parent Guideline Minimum Expectations At a minimum, those aspects of drug substances, excipients, container closure systems, and manufacturing processes that are critical to product quality should be determined and control strategies justified. Optionality In addition, the applicant can choose to conduct pharmaceutical development studies that can lead to an enhanced knowledge of product performance over a wider range of material attributes, processing options and process parameters. Flexibility The guideline also indicates areas where the demonstration of greater understanding of pharmaceutical and manufacturing sciences can create a basis for flexible regulatory approaches.
10 Q8 (R1) Annex At a minimum approach to Pharmaceutical Development Quality Target Product Profile Identification of potential critical quality attributes of the drug product Determining the critical quality attributes of the components of the drug product Selecting an appropriate manufacturing process Determining a control strategy
11 Q8 (R1) Annex Enhanced Approach (QbD) to Pharmaceutical Development Additionally:- Systematic evaluation, understanding Use of prior knowledge, risk assessment Functional relationship between material attributes and process parameters to product critical attributes Establishment of design space, real time release testing As a consequence facilitates continual improvement and innovation (ICH Q10)
12 Approaches to Pharmaceutical Development Aspect Minimal Approaches Enhanced, Quality by Design Approaches Overall Pharmaceutical Development Mainly empirical Developmental research often conducted one variable at a time Systematic, relating mechanistic understanding of material attributes and process parameters to drug product CQAs Multivariate experiments to understand product and process Establishment of design space PAT tools utilised illustrates some potential contrasts between what might be considered a minimal approach and an enhanced, quality by design approach We are responsible for ensuring the quality of product we manufacture
13 Quality by Design Quality by Design: A systematic approach to development that begins with predefined objectives and emphasizes product and process understanding and process control, based on sound science and quality risk management. QbD DESIGN SPACE QbD ADJECTIVE
14 QbD: Key Scientific Elements and Flow Target Product Profile Definition of Product Intended Use and predefinition of Quality targets (wrt clinical relevance, efficacy and safety) Prior Knowledge Summary of Prior Scientific Knowledge Initial Risk Assessment Product/ Process Dev. Overview of key actions taken to develop New Scientific Knowledge, e.g. DoE, PAT, Risk Assessment and Risk Control Product/ Process Design Space Summary of Scientific Understanding of Product and Process. Justification and description of design space Control Strategy Definition of Control Strategy Regulatory Flexibility Proposal of Regulatory Flexibility based on Product and Process Scientific Knowledge and Quality Risk Mgmt. Adapted from EFPIA
15 Thoughts on QbD QbD approach: Builds more science and knowledge into regulatory submissions Facilitates regulatory review and approval process Is optional and should not become a regulatory requirement as agreed to in ICH Q8 Will not necessarily be included in all submissions Can provide knowledge and understanding of critical product and process parameters and quality attributes DoE, PAT, etc. are tools that can facilitate QbD, but may not always be necessary
16 Definitions for CQA & CPP Critical Quality Attribute A physical, chemical, biological or microbiological property or characteristic that should be within an appropriate limit, range, or distribution to ensure the desired product quality. Critical Process Parameter A process parameter whose variability has an impact on a critical quality attribute and therefore should be monitored or controlled to ensure to process produces the desired quality. No Definition of Critical Flexibility on how a company determines criticality We are responsible for ensuring the quality of product we manufacture
17 Design Space Three Key Concepts: Design Space: the multidimensional combination and interaction of input variables (e.g., material attributes) and process parameters that have been demonstrated to provide assurance of quality. Working within the design space is not considered as a change. Movement out of the design space is considered to be a change and would normally initiate a regulatory post approval change process. Design space is proposed by the applicant and is subject to regulatory assessment and approval.
18 More about Design space What to include Select input variables that impact quality Where to apply a design space Guideline gives freedom to apply to one or more unit operations Importance of scale Design space will generally be established at small or pilot scale Need to establish the relationship on scale BUT Does not mean need to replicate work at scale Design Space vs Proven acceptable Ranges Design Space vs Edge of failure
19 CONTROL STRATEGY A control strategy is designed to consistently ensure product quality. Elements of a control strategy can include: Control of input material attributes Product Specifications Controls for unit operations that have an impact on downstream processing or end-product quality In-process or real-time release testing in lieu of end-product testing A monitoring program for verifying multivariate prediction models Enhanced understanding of product performance can justify the use of surrogate tests or support real-time release testing in lieu of end-product testing. A control strategy can include alternative elements We are responsible for ensuring the quality of product we manufacture
20 Real Time Release Testing Approach Traditional Release Approach LOD endpoint Granulation Milling Drying Granulation endpoint model to control dissolution NIR granule drying endpoint model Weight, thickness, hardness, disintegration, friability AQL DP release tests Description ID Content (HPLC) Impurity (HPLC) Uniformity (Mass) Dissolution Milling Blending Lubrication Compression Film Coating Laboratory NIR blend uniformity NIR composite assay On-line dosage uniformity by tablet press weight control Main compression height to control dissolution Description by AQL NIR for ID DP release tests Impurity (HPLC) GlaxoSmithKline
21 Benefits
22 QbD Everyone Benefits Reduce Post-approval regulatory submissions Recalls & manufacturing failures Uncertainty & Risk Cost Regulatory burden Non value regulatory &/or compliance exercises Need for process validation NDA documentation Improve Operational flexibility Process understanding Application of technology, e.g., PAT, modeling, scale Quality Regulatory review criteria Scientific/technical literacy among regulators Capitalization on experience Development efficiency Global harmonization
23 Benefits to industry better products risk-based regulatory decisions (reviews and inspections); manufacturing process improvements, within the approved design space described in the dossier, without further regulatory review; reduction of post-approval submissions; real-time release testing, leading to a reduction of end product release testing. We are responsible for ensuring the quality of product we manufacture
24 Regulatory Flexibility
25 Flexible Regulatory Approaches Objective: greater empowerment to self-manage innovation and improvement Enhanced product and process understanding (multi-variate) leading to Design Space Pharm Quality Systems (Q10) plus Quality Risk Management (Q9) Flexible Approaches This should not be considered to be about de-regulation Adapted from Dr J Berridge
26 Flexible Regulatory Processes Investment by Industry in enhanced process and product understanding should lead to more flexible regulatory approaches More meaningful and realistic specifications Parametric/real-time release Skip-lot testing Flexible, adaptive and learning (manufacturing and analytical) processes Reduction in routine commitments (e.g., stability) Reduction in categorisation of post-approval changes (pre-approval -> notification) We are responsible for ensuring the quality of product we manufacture
27 Implementing QbD What are the next steps? How do we transition to the new quality paradigm? What are the hurdles and opportunities?
28 If only applying QbD was simple from R.Baum
29 Cost and Benefit of QbD Development & Manufacturing Costs Increased Resources (e.g., development costs, organizational planning) Current State Empirical development approach Quality by testing & inspection Frozen process with reactive changes Initiate QbD Efforts Decreased Expenses (e.g. manufacturing costs, compliance costs) Desired State Quality by design development Flexible process & continual improvement QbD Fully Realized QbD Implementation Progress From M.Nasr
30 Alternative QbD Investment QbD Way #1 QbD Way #2 $ Investment More Limited Knowledge at Launch Launch Launch IND Commercial IND Commercial Products launched at same time, at same quality Same overall investment in development
31 Summary Q8 and Q8(R1) provides an opportunity to share knowledge with regulator Application of QbD Approach to development benefits everyone BUT Is optional Companies are implementing enhanced approaches but takes time and will not always be applied to all products We are responsible for ensuring the quality of product we manufacture
32 THANK YOU
STRATEGIES FOR SUCCESSFUL SCALE-UP USING QUALITY BY DESIGN
STRATEGIES FOR SUCCESSFUL SCALE-UP USING QUALITY BY DESIGN CHRISTOPHER J POTTER ISPE ADVISOR AND CMC CONSULTANT 1 AGENDA Background ICH Guidelines Terms and Definitions Supporting Information ISPE publications
More informationChallenges of Implementation of ICH Q 8
Challenges of Implementation of ICH Q 8 A Regulatory Perspective Dr. Susanne Keitel BioKorea, Seoul, September 2007 Overview of the Presentation ICH Q 8: Background; EU Experience Design Space Associated
More informationQuality by Design. Innovate Design Development Create value. Correct definition of QbD and its relation to product and process development
Innovate Development Create value Quality by Correct definition of QbD and its relation to product and process development Dr John Loveluck 42 Technology Ltd +44 1480 302700 john.loveluck@42technology.com
More informationCMC Topics and PMDA s activities Yoshihiro Matsuda, Ph.D.
CMC Topics and PMDA s activities Yoshihiro Matsuda, Ph.D. Senior Scientist (for Quality) Pharmaceuticals and Medical Devices Agency (PMDA) MFDS Nov 11, 2016 1 Agenda Introduction of PMDA ICH Q12 QbD assessment
More informationTerrence Tougas. Dennis Sandell
Terrence Tougas Boehringer Ingeheim, Ridgefield, CT Dennis Sandell S5 Consulting, Lund, Sweden (c) 2011 Sandell & Tougas 1 Transforming the general concept of Quality into objective, well defined and actionable
More informationImplementation of ICH Q8 and QbD An FDA Perspective
ISPE, Yokohama, Japan June 9, 2006 Implementation of ICH Q8 and QbD An FDA Perspective Chi-wan Chen, Ph.D. Office of New Drug Quality Assessment Center for Drug Evaluation and Research Food and Drug Administration
More informationICH Q8, 9 & 10 and the Impact on the QP
1 ICH Q8, 9 & 10 and the Impact on the QP Peter H. Gough David Begg Associates phg@david-begg-associates.com 2 A New Approach to Regulation Approach to the regulation of pharmaceuticals is undergoing a
More informationQuality by Design and OINDP. Today s Presentation
Quality by Design and OINDP Setting the Stage John C Berridge IPAC-RS September 2008 Today s Presentation QbD definition Setting the stage from an ICH perspective Future Opportunities 2 QbD Definition
More informationAnalytical Methods and Sampling in the New Manufacturing Paradigm a Regulatory Perspective
Analytical Methods and Sampling in the New Manufacturing Paradigm a Regulatory Perspective Dr. Øyvind Holte Norwegian Medicines Agency EMA PAT team/ EDQM PAT working party 15 October, 2014, Heidelberg
More informationPMDA perspective on Quality by Design for pharmaceutical products
PMDA perspective on Quality by Design for pharmaceutical products Junichi Fukuchi, Ph.D. Office of Cellular and Tissue-based Products Pharmaceuticals and Medical Devices Agency (PMDA) Annual conference
More informationImplementing Quality Systems
Implementing Quality Systems CGMP By The Sea August 29, 2006 Chris Joneckis, Ph.D. Senior Advisor For CMC Issues Center For Biologics Evaluation And Research Add FDA Bar and Presentation Overview Driving
More informationQuality by Design, Clinical Relevance & Lifecycle Considerations
Quality by Design, Clinical Relevance & Lifecycle Considerations Robert Iser Acting Director Office of Process & Facilities / OPQ / CDER IFPAC 2016 1 FDA Quality Related Guidance and Initiatives Initiatives
More informationImportance of ICH Guidance in Fulfilling Process Validation Requirements
Importance of ICH Guidance in Fulfilling Process Validation Requirements Presented by: Gamal Amer All rights reserved. Do not copy without permission. Principal 1 Premier Compliance Services, Inc. Process
More informationQbD Application in Japan: PMDA Perspective
CMC Strategy Forum Japan 2013 Hotel Okura, Tokyo, Japan, December 9 10, 2013 QbD Application in Japan: PMDA Perspective Yasuhiro Kishioka, PhD. Reviewer Office of Cellular and Tissue based Products Pharmaceuticals
More informationFrom API to Formulated Product
From API to Formulated Product Jean-Marie Geoffroy, PhD Director, Product Development Takeda Global Research & Development 675 N Field Drive Lake Forest, IL 60045 jean-marie.geoffroy@tgrd.com Acknowledgments
More informationValue Paper. Are you PAT and QbD Ready? Get up to speed
Value Paper Are you PAT and QbD Ready? Get up to speed PAT and Quality-by-Design As PAT and Quality -by-design (QbD) become an integral part of the regulatory framework, automation group ABB argues more
More informationEDQM Conference. Quality of Medicines in a Globalised World: Dreams and Reality
EDQM Conference Quality of Medicines in a Globalised World: Dreams and Reality 14-15 October 2010 Prague, Czech Republic 2010 EDQM, Council of Europe, All rights reserved Plenary Session Dr Moheb M. Nasr
More informationFeedback EMEA / Industry Discussion
Feedback EMEA / Industry Discussion Eli Lilly & Co Ltd Case Study: Use of In-Line Near-Infrared Spectroscopy to Monitor Segregation of a Pharmaceutical Powder Blend in a Tablet Press Martin Diller PhD,
More informationFuture of Pharmaceutical Quality and the Path to Get There
Future of Pharmaceutical Quality and the Path to Get There Lawrence Yu, Ph.D. Deputy Director, Office of Pharmaceutical Quality FDA Center for Drug Evaluation and Research INTERPHEX 2018, April 18, 2018,
More informationQUALITY: BRACKETING AND MATRIXING DESIGNS FOR STABILITY TESTING OF NEW VETERINARY DRUG SUBSTANCES AND MEDICINAL PRODUCTS
VICH GL 45 (QUALITY) BRACKETING AND MATRIXING April 2010 For Implementation at Step 7 QUALITY: BRACKETING AND MATRIXING DESIGNS FOR STABILITY TESTING OF NEW VETERINARY DRUG SUBSTANCES AND MEDICINAL PRODUCTS
More informationInnovative Approaches to Pharmaceutical Development and Manufacturing Seminar Series
CAMO European Pharmaceutical Seminars Jan/Feb 2009 Innovative Approaches to Pharmaceutical Development and Manufacturing Seminar Series The Increasing Need of Multivariate Analysis for Process Understanding
More informationTechnology Transfer Plays an Increasingly Important Role in Pharmaceutical Quality Systems
Technology Transfer Plays an Increasingly Important Role in Pharmaceutical Quality Systems A robust and secure manufactured product is the desired end result for pharmaceutical companies. Scale-up and
More informationPharmaceutical Manufacturing and Engineering Catalog Excerpt
Pharmaceutical Manufacturing and Engineering Catalog Excerpt PME 530 Introduction to Pharmaceutical Manufacturing Pharmaceutical manufacturing is vital to the success of the technical operations of a pharmaceutical
More informationGlobal GMP Harmonisation A Japanese Perspective
Global GMP Harmonisation A Japanese Perspective Yukio Hiyama, Ph.D. Chief, Third Section, Division of Drugs, National Institute of Health Sciences, The Ministry of Health Labour and Welfare, JAPAN ISPE
More informationCDER s Office of Pharmaceutical Quality (OPQ): Delivering on the 21 st Century Quality Goals
CDER s Office of Pharmaceutical Quality (OPQ): Delivering on the 21 st Century Quality Goals Lawrence X. Yu, Ph.D. Director (acting) Office of Pharmaceutical Science Food and Drug Administration IFPAC
More informationTECH TRANSFER University Joins Industry. Maite Aguado Pharmaceutical Technology PL Synthon Hispania
TECH TRANSFER University Joins Industry Maite Aguado Pharmaceutical Technology PL Synthon Hispania About me.. - Chemical Degree (UAB) / Master In Pharmaceuticals and Related Products(IUCT) / Master In
More informationThe Changing Face of Product and Process Development in the QbD Era. James Kraunsoe AstraZeneca Product Development UK/US
The Changing Face of Product and Process Development in the QbD Era James Kraunsoe AstraZeneca Product Development UK/US Disclaimer The views and opinions expressed in the following PowerPoint slides are
More informationICH Q12 (Pharmaceutical Product Lifecycle Management): PMDA Perspective
14 th DIA Japan Annual Meeting 2017 November 12-14, 2017 Tokyo Big Sight Ariake ICH Q12 (Pharmaceutical Product Lifecycle Management): PMDA Perspective Yasuhiro Kishioka, Ph.D. Principal Reviewer Office
More informationJUST SCRATCHING THE SERVICE
CONTRACT MANUFACTURING, PACKAGING & NEW EQUIPMENT TECHNOLOGY FOR THE BIOPHARM/PHARMACEUTICAL INDUSTRY OFFICIAL MEDIA SPONSOR OF W W W. P H A R M P R O. C O M V O L U M E 3 0, N U M B E R 4 M AY 2 0 1 5
More informationAssociation. Innovation in Medicines PDA: A Global. and Manufacturing. David Tainsh, GSK Keith Pugh, MHRA
Innovation in Medicines PDA: A Global and Manufacturing Association David Tainsh, GSK Keith Pugh, MHRA Joint Regulators/Industry QbD Workshop 28-29 January 2014 London, UK Introduction Current State We
More informationEU GMP Evolution or Revolution Scope and drivers for EU GMP changes. August Gordon Farquharson
EU GMP Evolution or Revolution Scope and drivers for EU GMP changes August 2015 Gordon Farquharson EU & PIC/S Harmonisation at IWG level now Slide 2 PharmOut 2015 EU & PIC/S Harmonisation (1) What does
More informationQbD/PAT Implementation: The Road to RTR From Science to Compliance
Quality by Design China 2013 April 17-18, 2013 Shanghai, China Pedro Hernandez, PhD 何盼多博士 Senior Director Quality Assurance - China http://www.frontagelab.com pedrohernandez@frontagelab.com.cn Background
More informationConsiGma TM, a platform for continuous processing
ConsiGma TM, a platform for continuous processing GEA Pharma Systems Where Inspiration meets Technology GEA Process Engineering / GEA Pharma Systems ConsiGma TM R&D and Manufacturing platform ConsiGma
More informationClaudio Pincus, President, The Quantic Group R. Owen Richards, President, Quantic Regulatory Services Daniel Pincus, Consultant, The Quantic Group
FDA Compliance and Regulatory Symposium Understanding the FDA s Latest cgmp Guidances: Opportunities and Pitfalls Claudio Pincus, President, The Group R. Owen Richards, President, Regulatory Services Daniel
More informationPROCESS ANALYTICAL TECHNOLOGY (PAT) - AS A CULTURE OF INNOVATION
International Journal of ChemTech Research CODEN( USA): IJCRGG ISSN : 0974-4290 Vol.1, No.4, pp 1339-1344, Oct-Dec 2009 PROCESS ANALYTICAL TECHNOLOGY (PAT) - AS A CULTURE OF INNOVATION Deepak D. Pokharkar*,
More informationLeader in Pharmaceutical Films
TSX-V: IGX OTCQX: IGXT Leader in Pharmaceutical Films Your Specialist in Contract Development & Manufacturing WE MAKE APPROVED DRUGS BETTER Our Mission We make approved drugs better, with next generation
More informationPharmaceutical Process Development
Announcing the following Seminar to be conducted by IVEPE-SEV Pharmaceutical Process Development Factors in Scale-Up, Process Validation and Regulatory Considerations Course Topics Include: Solid Dosage
More informationSymposium on Continuous Manufacturing of Pharmaceuticals Notes
1 2012 11 13 Symposium on Continuous Manufacturing of Pharmaceuticals Notes These are notes from the first open meeting regarding Novartis- MIT Center for Continuous Manufacturing (CCM). The meeting is
More informationGlobal Regulatory Update FDA, USP, EP and ICH Standards for Test Method Validation. Jane Weitzel
Global Regulatory Update FDA, USP, EP and ICH Standards for Test Method Validation Jane Weitzel mljweitzel@msn.com Jane Weitzel Biosketch Jane Weitzel has been working in analytical chemistry for over
More informationThe Process Analytical Technology Initiative: PAT and the Pharmacopeias
The Process Analytical Technology Initiative: PAT and the Pharmacopeias Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Science CDER, FDA EDQM Spring Conference, Cannes, 3-43 4 May 2004
More informationChallenges, benefits, case study
hallenges, benefits, case study Pharmaceutical development phases overview The new paradigm for development: Quality by Design (QbD) hallenges Benefits ase study losure and Q&A»»»»»» D. eriani Meet MINITAB,
More informationOffice of Pharmaceutical Quality Key Quality Initiatives
Office of Pharmaceutical Quality Key Quality Initiatives Ashley B. Boam, MSBE Director Office of Policy for Pharmaceutical Quality Office of Pharmaceutical Quality Center for Drug Evaluation and Research
More informationHow Process Models can Facilitate Quality Risk Management for Emerging Technologies
How Process Models can Facilitate Quality Risk Management for Emerging Technologies Thomas O Connor, Ph.D. FDA-AIChE Workshop on Adopting Continuous Manufacturing North Bethesda, MD March 2 th, 2016 2
More informationProcess Analytical Technology (PAT): A Real Time Quality Assurance
Review Article Process Analytical Technology (PAT): A Real Time Quality Assurance Punita Raj, N. Vishal Gupta* Pharmaceutical Quality Assurance group, JSS College of Pharmacy, JSS University, Sri Shivarathreeshwara
More informationBuilding Toward a Modern Pharmaceutical Manufacturing Sector: Encouraging Development and Adoption of Emerging Technology
Building Toward a Modern Pharmaceutical Manufacturing Sector: Encouraging Development and Adoption of Emerging Technology Sau (Larry) Lee, Ph.D. Associate Director for Science Office of Pharmaceutical
More information2008 Course Programs Schedule
2008 Course Programs Schedule Basic Laboratory Safety Laboratory Safety Biostatistics for the Non-Statistician - Basic Applied cgmps for Pharmaceutical and Allied Industries Good Clinical Practices (GCP)
More informationTimescales for Change A Look at Innovation in the Pharmaceutical Industry
Timescales for Change A Look at Innovation in the Pharmaceutical Industry 3rd FDA/PQRI Conference on Advancing Product Quality 23 Mar 2017 Robert F. Meyer, Ph.D. Global Pharmaceutical Commercialization
More informationInternational Journal of Pharma and Bio Sciences PROCESS ANALYTICAL TECHNOLOGY IMPLEMENTATION- PROGRESSION FOR A PHARMACEUTICAL INDUSTRY ABSTRACT
Research Article Analytical Chemistry International Journal of Pharma and Bio Sciences ISSN 0975-6299 PROCESS ANALYTICAL TECHNOLOGY IMPLEMENTATION- PROGRESSION FOR A PHARMACEUTICAL INDUSTRY SARAVANA KUMAR.V
More informationApplication of Visible-Residue Limit for Cleaning Validation Richard J. Forsyth and Vincent Van Nostrand By Richard J. Forsyth,Vincent Van Nostrand
October 2, 2005 Application of Visible-Residue Limit for Cleaning Validation Richard J. Forsyth and Vincent Van Nostrand By Richard J. Forsyth,Vincent Van Nostrand Pharmaceutical plants must have visually
More informationUpdate on Lessons Learned from the EMA-FDA QbD Pilot
Update on Lessons Learned from the EMA-FDA QbD Pilot IFPAC 2014 Annual Meeting 22 January 2014 Sharmista Chatterjee, Ph.D. CMC Lead for QbD, ONDQA/OPS/CDER/FDA Background One of the projected outcomes
More informationHow CDER is Encouraging Adoption of Emerging Technologies in Pharmaceutical Industry
How CDER is Encouraging Adoption of Emerging Technologies in Pharmaceutical Industry Moderator: Lawrence Yu Speakers: Thomas O Connor & Sharmista Chatterjee Emerging Technology: A Key Enabler for Modernizing
More informationFDA s Evolving Approach to Pharmaceutical Quality
FDA s Evolving Approach to Pharmaceutical Quality Lawrence Yu, Ph.D. Deputy Director, Office of Pharmaceutical Quality FDA Center for Drug Evaluation and Research 10th Annual FDA Inspections Summit Nov.
More informationAnalytical Development Labs
Analytical Development Labs S-Matrix ADL Purdue Technology Center 5225 Exploration Drive Suite S-2357 Indianapolis, IN 46241 USA URL: www.smatrix.com Overview Major Pharmaceutical companies worldwide use
More informationThe International Pharmacopoeia Overview
The International Pharmacopoeia Overview Prepared by Caroline Mendy Technical Officer - Quality Assurance and Safety: Medicines The International Pharmacopoeia P Content & Scope WHO Expert Committee on
More informationSection heading. Strapline sub-heading
Section heading Strapline sub-heading Smart every time NextPharma stands out as your pharmaceutical development and manufacturing partner with fast, flexible and tailored solutions for markets worldwide
More informationTechnology transfer in pharmaceutical industry- A Review
Popat B. Mohite and Sachin V. Sangle / International Journal of Advances in Pharmaceutics 2017; 06(01): 01-07. 1 International Journal of Advances in Pharmaceutics E-ISSN: 2320-4923; P-ISSN: 2320-4931
More informationTechnically Unavoidable Particles Profile (TUPPs) Guide
Technically Unavoidable Particles Profile (TUPPs) Guide Priscilla Zawislak Global Regulatory Affairs Manager Ashland Inc. Chair Elect, IPEC-Americas pszawislak@ashland.com www.ipecamericas.org 1 Agenda
More informationClaus Mortensen, Medicines Inspector. Danish Medicines Agency. Member of the EMEA PAT team
Claus Mortensen, Medicines Inspector Danish Medicines Agency Member of the EMEA PAT team EMEA progress and status what is needed to document scientific understanding in a PAT application EMEA PAT team
More informationSubmission of comments on Review of the Variations Guidelines (EC 1234/2008)
12 July 2012 Submission of comments on Review of the Variations Guidelines (EC 1234/2008) Comments from: Name of organisation or individual Leem Please note that these comments and the identity of the
More informationEmbracing Quality by Design. Applying QbD concepts can help CMOs create value
Embracing Quality by Design Applying QbD concepts can help CMOs create value By Russ Somma, Ph.D. and Andrew A. Signore, PE, PMP-DBIA, CPIP SommaTech, LLC Integrated Project Services (IPS) THE PHARMACEUTICAL
More informationOffice of Pharmaceutical Quality: Why, What, and How?
Office of Pharmaceutical Quality: Why, What, and How? Lawrence Yu, Ph.D. Deputy Director, Office of Pharmaceutical Quality FDA Center for Drug Evaluation and Research NIPTE Annual Scientific Conference
More informationICH Q8 / ICH Q11 Training Course
ICH Q8 / ICH Q11 Training Course From QbD to Process Validation Speakers: Dr Thomas Hille LTS Lohmann Therapie- Systeme AG Dr Øyvind Holte Norwegian Medicines Agency, EDQM PAT working party/ EMA PAT team
More informationRequirements in Other Countries PQRI+USP EI Workshop; Rockville, MD, Dr. Helmut Rockstroh
Requirements in Other Countries PQRI+USP EI Workshop; Rockville, MD, 2015 Dr. Helmut Rockstroh Overview Introduction - Scope Pharmacopoeial + HA Positions Examples / Case Studies Discussion 2 Introduction:
More informationTechnology to meet the needs of patients around the world
Technology to meet the needs of patients around the world Dr. Michael Thien, Senior Vice President Global Science, Technology and Commercialization Merck & Co., Inc. Our Past Scientific approach applied
More informationImpact of ICH Q9 and the application of Risk Management
Safeguarding public health Impact of ICH Q9 and the application of Risk Management An inspector s perspective on the impact on inspectional approaches and expectations Ian Thrussell Strategy and Development
More informationPHARMACEUTICAL QUALITY MANAGEMENT SYSTEM: A REVIEW
PHARMACEUTICAL QUALITY MANAGEMENT SYSTEM: A REVIEW Available online at www.ijdra.com REVIEW ARTICLE Sharma S*, Bodla R.B., Shweta S, Pathak D.P. Delhi Institute of Pharmaceutical Sciences and Research,
More informationMAH Responsibilities including the Management of CMOs. QP Forum Workshop. Robert Byrne and Eoin Duff Quality Assurance Alexion Pharmaceuticals
MAH Responsibilities including the Management of CMOs QP Forum 2017 - Workshop Robert Byrne and Eoin Duff Quality Assurance Alexion Pharmaceuticals 25 th April 2017 Alexion Pharmaceuticals in Ireland A
More informationReview on Technology Transfer in Pharmaceutical Industry
Available online on www.ijpqa.com International Journal of Pharmaceutical Quality Assurance 2016; 7(1); 7-14 Review Article ISSN 0975 9506 Review on Technology Transfer in Pharmaceutical Industry Manu
More informationWHO Regulatory Systems Strengthening Program
WHO Regulatory Systems Strengthening Program MVP RHT RSS CRS www.who.int Minimal capacity met Eligibility for vaccine PQ WHO listed NRAs WHO NRA 5 step capacity building Development of NRA benchmarking
More informationTHE LABORATORY ANIMAL BREEDERS ASSOCIATION OF GREAT BRITAIN
THE LABORATORY ANIMAL BREEDERS ASSOCIATION OF GREAT BRITAIN www.laba-uk.com Response from Laboratory Animal Breeders Association to House of Lords Inquiry into the Revision of the Directive on the Protection
More informationALL RAW MATERIALS ARE NOT CREATED EQUAL.
ALL RAW MATERIALS ARE NOT CREATED EQUAL. Meet Diagnostics Elite DIAGNOSTIC SOLUTIONS Reimagine what s possible. REDUCE RISK. INCREASE CONSISTENCY. The Diagnostics Elite program is more than just a set
More informationGSK s Development of Novel Oral Delivery Technologies Perspectives
GSK s Development of Novel Oral Delivery Technologies Perspectives Mark Wilson Director, PTS, R&D GlaxoSmithKline Pharmaceuticals GSK Established a Technology Incubator To Develop Drug Delivery Systems
More informationAddition of D4, D5 and D6 to SVHC candidate list
Addition of D4, D5 and D6 to SVHC candidate list Contents What are silicones?... 2 What are D4, D5 and D6 and where are they used?...2 What does SVHC mean?......2 Who made the SVHC decision?... 2 Why were
More informationPDA 71 Years of Connecting People, Science and Regulation
PDA 71 Years of Connecting People, Science and Regulation 1 I m happy to be here. Bom Dia. Estou feliz por estar aqui. Richard M. Johnson PDA President & CEO since 2009 38 years experience in US and International
More informationTechnology Evaluation. David A. Berg Queen s University Kingston, ON November 28, 2017
Technology Evaluation David A. Berg Queen s University Kingston, ON November 28, 2017 About me Born and raised in Alberta Queen s alumni (as well as University of Calgary & Western) Recently retired from
More informationICH Q-IWG Integrated Training Programme
Implementation of ICH Q8, Q9, Q10 ICH Q-IWG Integrated Training Programme International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Disclaimer
More informationBeware the non-critical excipient
Beware the non-critical excipient Dr Brian A Carlin Director Open Innovation, Chair IPEC QbD Committee brian.carlin@fmc.com ExcipientFest 2012 1 Understand your raw materials http://www.ich.org/uploads/media/q-iwg_web_basic_training.pdf
More informationWorkshop 240 GRANULATION & TABLETING PROCESS Innovative process and tools to achieve the perfect OSD product April 2018
Workshop 240 GRANULATION & TABLETING PROCESS Innovative process and tools to achieve the perfect OSD product. 17 19 April 2018 WHY PARTICIPATING? This workshop on granulation and tableting is a perfect
More informationHealth Care Ltd 3M United Kingdom PLC Every day, 3M people find new ways to make amazing things happen. Wherever they are, whatever they do, the company s customers know they can rely on 3M to help make
More informationE5 Implementation Working Group Questions & Answers (R1) Current version dated June 2, 2006
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE E5 Implementation Working Group & (R1) Current version dated June 2, 2006 ICH Secretariat,
More informationConsiderations for Leachables and Extractables in a Quality by Design Environment
IPAC-RS 2006 Conference Inhalation and Nasal Drugs: The Regulatory Landscape Considerations for Leachables and Extractables in a Quality by Design Environment Daniel L. Norwood, Ph.D. Director Physical
More informationGlatt Technology Center
Glatt Technology Center Pharmaceutical Development Formulation Development Process Development Scale-Up Contract Manufacturing Equipment Design Technology Transfer Full Service Development. Scale-Up. Production.
More informationVisioNIR. High Speed NIR Spectrometer for 100% Process Inspection
VisioNIR High Speed NIR Spectrometer for 100% Process Inspection Table of Content Introduction... 2 visiotec VisioNIR High Speed NIR Spectrometer: Your Way to PAT... 2 The benefits of the VisioNIR system...
More informationVENUE. 2 DAY WORKSHOP On FDA Penalties for Regulatory Non-Compliance in the Pharmaceuticals Industry in Review , JAN San Diego CA
WORLD COMPLIANCE SEMINARS SPEAKER:- BRIAN G. NADEL President of Brian G. Nadel, GMP Consulting, LLC. 2 DAY WORKSHOP On FDA Penalties for Regulatory Non-Compliance in the Pharmaceuticals Industry - 2017
More informationThe Transition to Model-Based Drug Development. Phase 1: Formalizing the Pharmacometric Process
1780 Wehrle Drive Suite 110 Buffalo, New York 14221 716.633.3463 cognigencorp.com The Transition to Model-Based Drug Development Phase 1: Formalizing the Pharmacometric Process By Thaddeus H. Grasela,
More informationUSP Research & Innovation Program
USP Research & Innovation Program Ding Ming, Ph.D. Vice president, Research & Innovation United States Pharmacopeial Convention (USP) October 13, 2016 USP Programs and Products Impact Millions Worldwide
More informationWorkshop: GRANULATION & TABLETING New requirements for an established technology - robustness, efficiency and quality.
Workshop: GRANULATION & TABLETING New requirements for an established technology - robustness, efficiency and quality. 12 14 April 2016 WHY PARTICIPATE? This workshop on granulation and tableting is a
More informationProgressive Licensing and the Modernization of the Canadian Regulatory Framework
Progressive Licensing and the Modernization of the Canadian Regulatory Framework Workshop on Implementation of ICH Quality Guidelines Beijing, China 3-5 December, 2008 Mike Ward Health Canada 1 DISCLAIMER
More informationQuality Regulation under Revised Pharmaceutical Affair Law
Quality Regulation under Revised Pharmaceutical Affair Law Yukio Hiyama, Ph.D. Division of Drugs, National Institute of Health Sciences, the Ministry of Health, Labour and Welfare, Japan E mail hiyama@nihs.go.jp
More informationProcess Validation to Improve Food Safety Meat and Poultry. James S Dickson Inter-Departmental Program in Microbiology Department of Animal Science
Process Validation to Improve Food Safety Meat and Poultry James S Dickson Inter-Departmental Program in Microbiology Department of Animal Science Validation vs. Verification Those activities, other than
More informationASEPTIC PROCESSING, TODAY AND FUTURE
ASEPTIC PROCESSING, TODAY AND FUTURE Dublin, Ireland, 4 October 2018 Marco Delgado Rueda ALL RIGHTS RESERVED 2018 PAREXEL INTERNATIONAL CORP. AGENDA Today s Reality and Needs Issues and Probable Causes
More informationEDQM Conference. Quality of Medicines in a Globalised World: Dreams and Reality
EDQM Conference Quality of Medicines in a Globalised World: Dreams and Reality 14-15 October 2010 Prague, Czech Republic 2010 EDQM, Council of Europe, All rights reserved Dr Georges France Ms Suzette Kox
More informationTraining. Education CALENDAR FEDEGARI TECH CENTERS DM#407036
2016 CALENDAR COLLABORATION IN THE LIFE SCIENCES WORLD Valued customer, The need to increase efficiency and reliability in pharmaceutical manufacturing presents firms with unique opportunities to develop
More informationSpeed Innovation Happiness. Corporate Overview
Corporate Overview Contents Bilcare Overview Businesses Business Strategy Financial Overview 2 Bilcare Overview 3 Bilcare Overview Our Objective Vision Delivering Innovation Transforming Lives Values Speed
More informationInter-Association Task Force
Inter-Association Task Force Presentation to EMA Workshop Prevention of Drug Shortages Based on Quality and Manufacturing Issues 9 th October 2015 1 Topics for Today Background and history of task force
More informationIntellectual Property, Vaccine Production and Technology Transfer
Intellectual Property, Vaccine Production and Technology Transfer Vaccine Industry Perspective P. Fournier, On behalf of IFPMA Bio Group 19-20 April 2004, WHO HQ, Geneva 1 OUTLINE General considerations
More informationWHITE PAPER FACILITY FOCUS: Next Generation Aseptic Manufacturing: An Eye-Opening Peek into the Future. By: Hite Baker
WHITE PAPER FACILITY FOCUS: Next Generation Aseptic Manufacturing: An Eye-Opening Peek into the Future By: Hite Baker August 2017 Introduction This Facility Focus Survey Report explores how to design sterile
More informationProgress in FDA s Drug Product Quality Initiative. Janet Woodcock, M.D. November 13, 2003
Progress in FDA s Drug Product Quality Initiative Janet Woodcock, M.D. November 13, 2003 Impetus for Initiative: Modernization and continuous improvement in pharmaceutical manufacturing sector slow compared
More informationHealth Based Exposure Limits (HBEL) and Q&As
Health Based Exposure Limits (HBEL) and Q&As The EMA guideline (EMA/CHMP/ CVMP/ SWP/169430/2012) & EMA/CHMP/CVMP/SWP/463311/2016 Graeme McKilligan, UK, MHRA. Content Intent of HBEL Post Implementation
More informationpeace of mind For from development to commercial supply
For peace of mind from development to commercial supply aesica-pharma.com weshouldtalk@aesica-pharma.com @aesica CorporateBroEng_v2 0814 @ Aesica 2014 Your full service CDMO Our vision: To be the number
More information